GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hualan Biological Engineering Inc (SZSE:002007) » Definitions » Total Assets

Hualan Biological Engineering (SZSE:002007) Total Assets : ¥16,269 Mil (As of Mar. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Hualan Biological Engineering Total Assets?

Hualan Biological Engineering's Total Assets for the quarter that ended in Mar. 2024 was ¥16,269 Mil.

Warning Sign:

If a company builds assets at 29.8% a year, faster than its revenue growth rate of 8.8% over the past 5 years, it means that the company may be getting less efficient.

During the past 12 months, Hualan Biological Engineering's average Total Assets Growth Rate was 3.70% per year. During the past 3 years, the average Total Assets Growth Rate was 29.30% per year. During the past 5 years, the average Total Assets Growth Rate was 29.80% per year. During the past 10 years, the average Total Assets Growth Rate was 15.80% per year.

During the past 13 years, Hualan Biological Engineering's highest 3-Year average Total Assets Growth Rate was 38.80%. The lowest was 0.40%. And the median was 23.40%.

Total Assets is connected with ROA %. Hualan Biological Engineering's annualized ROA % for the quarter that ended in Mar. 2024 was 6.47%. Total Assets is also linked to Revenue through Asset Turnover. Hualan Biological Engineering's Asset Turnover for the quarter that ended in Mar. 2024 was 0.05.


Hualan Biological Engineering Total Assets Historical Data

The historical data trend for Hualan Biological Engineering's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hualan Biological Engineering Total Assets Chart

Hualan Biological Engineering Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7,583.20 10,038.64 11,537.24 14,743.38 16,105.78

Hualan Biological Engineering Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15,081.33 14,492.81 15,531.48 16,105.78 16,268.79

Hualan Biological Engineering Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Hualan Biological Engineering's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets=Total Equity (A: Dec. 2023 )+Total Liabilities (A: Dec. 2023 )
=13421.183+2684.601
=16,106

Hualan Biological Engineering's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets=Total Equity (Q: Mar. 2024 )+Total Liabilities (Q: Mar. 2024 )
=13707.625+2561.163
=16,269

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hualan Biological Engineering  (SZSE:002007) Total Assets Explanation

Total Assets is connected with ROA %.

Hualan Biological Engineering's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %=Net Income (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=1047.096/( (16105.783+16268.788)/ 2 )
=1047.096/16187.2855
=6.47 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Hualan Biological Engineering's Asset Turnover for the quarter that ended in Mar. 2024 is

Asset Turnover
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=787.309/( (16105.783+16268.788)/ 2 )
=787.309/16187.2855
=0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Hualan Biological Engineering Total Assets Related Terms

Thank you for viewing the detailed overview of Hualan Biological Engineering's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Hualan Biological Engineering (SZSE:002007) Business Description

Traded in Other Exchanges
N/A
Address
No. A1 Hualan Avenue, Henan Province, Xinxiang, CHN, 453003
Hualan Biological Engineering Inc is a China-based biopharmaceutical company. It is engaged in the research, development, production, and commercialization of plasma products, viral vaccines, bacterial vaccines, and recombinant proteins and other biologics. The plasma products offered by the company include Human albumin, Human fibrinogen, Human tetanus immunoglobulin and others. The vaccines products include Recombinant hepatitis B vaccine, Inactivated influenza vaccine and other. It also offers gene products such as Monoclonal Antibody for tumor, autoimmune diseases, infectious diseases, transplant rejection, and Recombinant monoclonal antibodies.
Executives
An Kang Directors, executives
Pan Ruo Wen Executives
An Wen Qi Executives
Wang Qi Ping Directors, executives
Fan Bei Directors, executives
Ma Xiao Wei Executives
Xie Jun Min Directors, executives
Zhang Bao Xian Executives
Lv Cheng Yu Securities Affairs Representative
Zhang Jin Gang Independent director
Wang Li Ting Independent director
Ma Li Supervisors
Sun Zhen Guo Supervisors
Chen Lei Shan Supervisors
Yang Bao Ping Supervisors

Hualan Biological Engineering (SZSE:002007) Headlines

No Headlines